← Eichor
Study identifier: NCT04892173 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

Condition: Carcinoma, Squamous Cell  ·  Sponsor: Johnson & Johnson Enterprise Innovation Inc.

PhasePhase 3
Planned participants500
Who can joinAll sexes, 60 Years to no upper limit
Healthy volunteersNo

About this study

This is a global, open-label, randomized, 2-arm, Investigator's choice Phase 3 (Pivotal Stage) study to investigate the efficacy and safety of JNJ-90301900 (NBTXR3) / radiation therapy (RT)±cetuximab versus RT±cetuximab in treatment-naïve, platinum-ineligible, elderly participants with locally advanced head and neck squamous cell carcinoma (LA-HNSCC).

This description comes directly from the study's public registry record.

Talk to the study team

Study Contact  ·  844-434-4210  ·  Participate-In-This-Study1@its.jnj.com

Always discuss trial participation with your own doctor first.

Locations (191)

University of Alabama at BirminghamBirmingham, Alabama, United StatesRecruiting
City of HopeDuarte, California, United StatesRecruiting
University of California at San Diego Moores Cancer CenterLa Jolla, California, United StatesRecruiting
Memorial Radiation Oncology Medical Group Laguna HillsLaguna Hills, California, United StatesCompleted
UCLA Hematology OncologyLos Angeles, California, United StatesRecruiting
Hoag Memorial HospitalNewport Beach, California, United StatesCompleted
University of California San FranciscoSan Francisco, California, United StatesRecruiting
George Washington University Cancer CenterWashington D.C., District of Columbia, United StatesRecruiting
Mayo Clinic JacksonvilleJacksonville, Florida, United StatesRecruiting
AdventHealth OrlandoOrlando, Florida, United StatesRecruiting
Moffitt Cancer CenterTampa, Florida, United StatesRecruiting
Emory University Hospital MidtownAtlanta, Georgia, United StatesRecruiting

+ 179 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04892173